 |
Healthy Mom Healthy Baby TennesseeDoctors and guests discuss racial disparities, addiction and more in pregnancy and infant birth. Author: Tennessee Initiative for Perinatal Quality Care
The Tennessee Initiative for Perinatal Quality Care (TIPQC) presents Healthy Mom Healthy Baby Tennessee. This podcast is a discussion with medical providers and other industry experts on all aspects of perinatal health. Tennessee Initiative for Perinatal Quality Care (TIPQC) seeks to improve health outcomes for mothers and infants in Tennessee by engaging key stakeholders in a perinatal quality collaborative that will identify opportunities to optimize maternal and infant outcomes and implement data-driven provider- and community-based performance improvement initiatives. Visit www.tipqc.org for more information on our improvement work in Tennessee. No content or comments made in any TIPQC Healthy Mom Healthy Baby Tennessee Podcast is intended to be comprehensive or medical advice. Neither healthcare providers nor patients should rely on TIPQCs Podcasts in determining the best practices for any particular patient. Additionally, standards and practices in medicine change as new information and data become available and the individual medical professional should consult a variety of sources in making clinical decisions for individual patients. TIPQC undertakes no duty to update or revise any particular Podcast. It is the responsibility of the treating physician or health care professional, relying on independent experience and knowledge of the patient, to determine appropriate treatment. TIPQC is funded under a Grant Contract with the State of Tennessee. This podcast is brought to you through a cooperative agreement with the Alliance for Innovation on Maternal Health (AIM). Connect with us: www.tipqc.org www.facebook.com/tipqc1 www.twitter.com/TennesseePQC www.instagram.com/tipqc1 www.youtube.com/channel/UCOZ0gpRWzimImh5XfsQdcvg/ Language: en Genres: Education, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
EO: 203 GLP1s and Pregnancy with Dr. Kerri Brackney
Episode 203
Friday, 5 December, 2025
In this episode of Healthy Mom Healthy Baby Tennessee, Dr. Linley Wolfe interviews Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis, about GLP-1 receptor agonist medications (commonly known as Ozempic, Wegovy, and similar drugs) and their implications for pregnancy. The discussion covers how these medications work, their dramatic effects on weight loss and diabetes management, and the emerging phenomenon of "Ozempic babies" - unintended pregnancies occurring in women taking these medications. Dr. Brackney provides guidance on when to discontinue these medications before conception, discusses limited safety data in pregnancy, and explains what monitoring is recommended for women who become pregnant while taking GLP-1s. Both physicians share their personal experiences with these medications and express hope for future research on postpartum use.Episode Highlights00:00:04: Welcome to Healthy Mom, Healthy Baby Tennessee podcast, brought to you by the Tennessee Initiative for Perinatal Quality Care (TIPQC), which exists to improve health outcomes for mothers and infants in Tennessee 00:00:46: Dr. Linley Wolfe introduces Dr. Carrie Brackney, a maternal-fetal medicine physician in Memphis who has been practicing as a perinatologist for three years after working as a general OB-GYN for nine years00:01:32: Dr. Brackney describes her passion for caring for women with complex pregnancies and helping them find joy during challenging times00:02:03: Dr. Wolfe introduces the topic of GLP-1 medications, noting they have been revolutionary for people struggling with weight00:02:38: Dr. Brackney explains that GLP-1 receptor agonists work by activating glucagon-like peptide one receptors, regulating blood sugar, reducing appetite, and slowing digestion through multiple mechanisms00:03:46: Discussion of how GLP-1 medications have been around for diabetes treatment but have been increasingly used for weight loss over the last four to five years00:04:04: Dr. Brackney notes these medications are also being used for patients with cardiovascular conditions and kidney disease, showing decreased complications00:04:28: Dr. Wolfe mentions recent approval for people who are overweight with sleep apnea, predicting more indications will emerge00:04:42: Cost identified as one of the biggest barriers to these medications becoming more popular00:05:01: Dr. Brackney reports that semaglutide and tirzepatide show potential for over 10% weight loss, while liraglutide shows 5-15% total weight loss00:05:49: Discussion of side effects, with nausea and constipation being the most common, though they are treatable and many people adjust over time00:06:09: Dr. Wolfe asks about common brand names versus generic names for listener clarity00:06:25: Dr. Brackney lists brand names including Ozempic, Wegovy, Rybelsus (semaglutide), Trulicity (dulaglutide), Victoza and Saxenda (liraglutide), and Mounjaro (tirzepatide)00:07:02: Discussion of compounded medications versus manufacturer medications, with Dr. Brackney noting compounded versions are not FDA-regulated and therefore not considered as safe00:07:55: Dr. Wolfe transitions to discussing pregnancy and the phenomenon of "Ozempic babies"00:08:51: Dr. Brackney explains that obesity reduces fertility, with obese women having three times higher risk of infertility and 40% higher miscarriage rates00:10:28: Discussion of how GLP-1 medications may interfere with contraceptive distribution in the body due to slowed gastric emptying00:11:04: Dr. Wolfe summarizes that better overall health, weight loss, and potential contraceptive interference all contribute to "Ozempic babies"00:11:27: Dr. Brackney recommends discontinuing GLP-1 medications at least one to two months before trying to get pregnant, noting limited data on ideal timing00:12:38: Discussion of the lack of...
